Compare Gilead Sciences, Inc. (GILD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sana Biotechnology Inc — how do they compare? Gilead Sciences, Inc. trades at $147.58 (market cap $181.41B), while Sana Biotechnology Inc trades at $2.96 (market cap $948.97M). The key difference: Gilead Sciences, Inc. is far larger — about 191.2× Sana Biotechnology Inc's market cap, and Gilead Sciences, Inc. pays a 2.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 108 Days and Sana Biotechnology Inc for 22 Days on average.
| GILD | SANA | |
|---|---|---|
Market Cap | $181.41B | $948.97M |
Volume | 4,265,683 | 2,464,651 |
Sector | Health | Health |
52-Week High | $155.80 | $5.92 |
52-Week Low | $110.56 | $2.68 |
Typical Hold Time | 108 Days | 22 Days |
Enterprise Value | $204.47B | $862.22M |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.68, up 0.87% today, near the consensus price target of $150. The stock shows a bullish technical trend with recent earnings beats in Q4 2025 and Q1 2026, though Q2 2026 posted a loss. Revenue grew to $29.44B in 2025, but net income margin turned negative at -10.64% for 2026. Positive sentiment is driven by expansion of HIV drug access in Latin America and a new research center opening.
Outlook is cautiously optimistic with strong analyst support (67% buy ratings) and a solid HIV franchise, but risks include profitability pressures and high debt. The stock offers potential upside to the $150 target, though investors should monitor earnings execution and pipeline progress amid competitive and regulatory challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
